Leap Therapeutics, Inc. Stock price

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.66 USD -4.32% Intraday chart for Leap Therapeutics, Inc. +4.31% -35.83%
Sales 2024 * - Sales 2025 * 25.86M Capitalization 68.1M
Net income 2024 * -69M Net income 2025 * -69M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.63 x
P/E ratio 2024 *
-1.18 x
P/E ratio 2025 *
-1.79 x
Employees 54
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.87%
More Fundamentals * Assessed data
Dynamic Chart
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Leap Therapeutics, Inc. - Special Call
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients CI
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating MT
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Top Premarket Decliners MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating MT
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating MT
More news

Latest transcript on Leap Therapeutics, Inc.

1 day-4.32%
1 week+4.31%
Current month-4.66%
1 month-6.67%
3 months-44.35%
6 months+90.00%
Current year-35.83%
More quotes
1 week
2.32
Extreme 2.3212
2.98
1 month
2.13
Extreme 2.125
3.00
Current year
2.13
Extreme 2.125
5.00
1 year
1.24
Extreme 1.235
10.20
3 years
1.24
Extreme 1.235
41.70
5 years
1.24
Extreme 1.235
41.70
10 years
1.24
Extreme 1.235
102.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-12-31
Chairman 69 10-12-31
Chief Tech/Sci/R&D Officer 45 20-08-23
Members of the board TitleAgeSince
Director/Board Member 72 15-12-31
Director/Board Member 63 16-12-31
Chairman 69 10-12-31
More insiders
Date Price Change Volume
24-03-28 2.66 -4.32% 192,513
24-03-27 2.78 +12.10% 191,777
24-03-26 2.48 +3.33% 101,183
24-03-25 2.4 -4.76% 276,900
24-03-22 2.52 -1.18% 107,881

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Leap Therapeutics, Inc. is a biotechnology company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company's pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. It also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.66 USD
Average target price
11.75 USD
Spread / Average Target
+341.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Leap Therapeutics, Inc. - Nasdaq